Amid concerns about MIRA Pharmaceuticals' cash burn, there are compelling reasons for optimism. The company has smartly reduced its cash burn by 8.1% in the past year, extending its cash runway to about 16 months as of September 2023. This indicates prudent financial management and a strategic approach to growth.
The partnership with Pharmaseed Ltd. to develop...
